🟢 Ionis Pharmaceuticals is trading 43.3% up in after-hours trading after Sefaxersen met Phase 3 primary endpoint

Ionis Pharmaceuticals is trading at $62.96, up 43.32%, after Sefaxersen met its Phase 3 primary endpoint, significantly reducing proteinuria in IgA nephropathy on September 23, 2026.

• The trial reported no new safety signals and will continue assessing kidney-function preservation.
• The move follows positive Phase 3 ulefnersen results announced September 22. Broader markets declined, but company-specific pipeline news is the stronger apparent catalyst.